Unsupervised PrEP in routine practice: a new challenge?

Abstract

Pre-exposure prophylaxis (PrEP) for the prevention of HIV infection with 300 mg daily tenofovir co-formulated with 200 mg emtricitabine is recommended as one prevention option for people who are at substantial risk of acquiring an HIV infection. We report the case of a 28-year-old man who has sex with men and who was referred to our unit for a primary HIV infection with positive p18, p24 and gp160 bands on Western blot analysis but with a low HIV plasma viral load. Although HIV misdiagnosis should always be considered in cases of atypical seroconversion pattern with a low viral burden, unsupervised PrEP should be systematically investigated.

• Authors: Hélène Laroche, Caroline Lions, Olivia Zaegel-Faucher, Catherine Tamalet, Isabelle Poizot-Martin
• Journal: International journal of STD & AIDS (Int J STD AIDS) Vol. 30 Issue 7 Pg. 715-717 (06 2019) ISSN: 1758-1052 [Electronic] England
• PMID: 30975069 (Publication Type: Journal Article)

Chemical References

• Anti-HIV Agents
• Tenofovir
• Emtricitabine

Topics

• Adult
• Anti-HIV Agents (blood, therapeutic use)
• Emtricitabine (therapeutic use)
• HIV Infections (blood, diagnosis, drug therapy)
• HIV-1 (drug effects)
• Homosexuality, Male
• Humans
• Male
• Pre-Exposure Prophylaxis
• Tenofovir (therapeutic use)
• Viral Load